The estimated Net Worth of James C Momtazee is at least $3.76 Milione dollars as of 29 December 2021. Mr. Momtazee owns over 80,000 units of BridgeBio Pharma Inc stock worth over $2,476,863 and over the last 21 years he sold BBIO stock worth over $87,590. In addition, he makes $1,199,990 as Independent Director at BridgeBio Pharma Inc.
James has made over 3 trades of the BridgeBio Pharma Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 80,000 units of BBIO stock worth $1,160,000 on 29 December 2021.
The largest trade he's ever made was buying 80,000 units of BridgeBio Pharma Inc stock on 29 December 2021 worth over $1,160,000. On average, James trades about 2,525 units every 87 days since 2003. As of 29 December 2021 he still owns at least 88,491 units of BridgeBio Pharma Inc stock.
You can see the complete history of Mr. Momtazee stock trades at the bottom of the page.
James C. Momtazee serves as Independent Director of the Company. He is a Member of KKR, and he has been employed by Kohlberg Kravis Roberts & Co. L.P., a private equity and alternative asset management firm, since 1996. Mr. Momtazee currently serves on the board of directors of PRA Health Sciences, Inc. (Nasdaq: PRAH), a global contract research organization as well as several private companies. He previously served on the boards of directors of Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a biopharmaceutical company, from 2004 to 2014, HCA Healthcare Inc. (formerly HCA Holdings Inc.; NYSE: HCA), a health care services company, from 2006 to 2014, and Entellus Medical, Inc., a medical technology company, from 2017 to 2018. He received an A.B. from Stanford University and an M.B.A. from the Stanford Graduate School of Business.
As the Independent Director of BridgeBio Pharma Inc, the total compensation of James Momtazee at BridgeBio Pharma Inc is $1,199,990. There are 9 executives at BridgeBio Pharma Inc getting paid more, with Neil Kumar having the highest compensation of $26,334,100.
James Momtazee is 48, he's been the Independent Director of BridgeBio Pharma Inc since 2016. There are 13 older and 9 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
James's mailing address filed with the SEC is C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304.
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo e Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include: